Lenalidomide Grindeks (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, altering its substrate specificity. This leads to degradation of transcription factors that support malignant cell survival, resulting in reduced angiogenesis, enhanced immune‑mediated tumor cell killing, and induction of apoptosis in cancerous cells.

The prescribed dose of Lenalidomide Grindeks is individualized by the treating physician based on the specific indication, disease stage, patient renal function, prior therapies, and tolerability. No fixed dosing regimen is provided here; the prescriber sets the appropriate regimen.

Lenalidomide is classified as having an unknown pregnancy category and is contraindicated in pregnancy because of teratogenic risk. Women of childbearing potential must use effective contraception, and breastfeeding is not recommended while receiving the drug.

To order Lenalidomide Grindeks, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory imide drug (IMiD) class, but lenalidomide is more potent, has a more favorable safety profile, and exhibits reduced neurotoxicity. Clinical studies show higher response rates in multiple myeloma and fewer severe peripheral neuropathy events compared with thalidomide.

Store Lenalidomide Grindeks at ambient temperature below 25 °C. Keep the product in its original packaging, protect it from moisture and light, and ensure the container is tightly closed to maintain stability.

Lenalidomide Grindeks is administered orally, usually as a tablet taken with or without food as directed by the prescribing clinician. The exact schedule (e.g., daily or on specific days of a treatment cycle) is determined by the treating physician.

Serious risks include venous thromboembolism, severe neutropenia leading to infection, secondary primary malignancies, severe skin reactions such as Stevens‑Johnson syndrome, and hepatic toxicity. Patients should be monitored closely for these events throughout therapy.

Lenalidomide Grindeks should not be used by patients who are pregnant, are unable to comply with required contraception, have uncontrolled infections, or have severe renal impairment without dose adjustment. It is also contraindicated in individuals with known hypersensitivity to lenalidomide or any component of the formulation.